Amarin Corp. PLC ADR (AMRN): Price and Financial Metrics


Amarin Corp. PLC ADR (AMRN): $5.16

-0.01 (-0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

AMRN POWR Grades


  • Value is the dimension where AMRN ranks best; there it ranks ahead of 92.02% of US stocks.
  • The strongest trend for AMRN is in Momentum, which has been heading down over the past 51 weeks.
  • AMRN's current lowest rank is in the Momentum metric (where it is better than 9.51% of US stocks).

AMRN Stock Summary

  • With a price/earnings ratio of 473.08, Amarin Corp Plc P/E ratio is greater than that of about 98.54% of stocks in our set with positive earnings.
  • For AMRN, its debt to operating expenses ratio is greater than that reported by only 6.4% of US equities we're observing.
  • With a year-over-year growth in debt of -72.06%, Amarin Corp Plc's debt growth rate surpasses just 4.68% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Amarin Corp Plc, a group of peers worth examining would be ITI, IRMD, CMCO, BFAM, and AVNS.
  • Visit AMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.amarincorp.com.

AMRN Valuation Summary

  • AMRN's price/sales ratio is 3.5; this is 69.16% lower than that of the median Healthcare stock.
  • Over the past 130 months, AMRN's EV/EBIT ratio has gone up 152.5.
  • Over the past 130 months, AMRN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for AMRN.

Stock Date P/S P/B P/E EV/EBIT
AMRN 2021-08-31 3.5 3.3 497.8 148.5
AMRN 2021-08-30 3.5 3.4 506.9 151.7
AMRN 2021-08-27 3.6 3.4 514.3 154.2
AMRN 2021-08-26 3.6 3.5 517.0 155.2
AMRN 2021-08-25 3.7 3.6 534.4 161.3
AMRN 2021-08-24 3.7 3.5 528.0 159.1

AMRN Growth Metrics

  • The 4 year net income to common stockholders growth rate now stands at 87.22%.
  • Its 2 year price growth rate is now at 163.32%.
  • The 4 year revenue growth rate now stands at 459.8%.
Over the past 15 months, AMRN's revenue has gone up $108,938,000.

The table below shows AMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 620.408 -61.227 4.32
2021-03-31 601.237 -44.587 0.927
2020-12-31 614.06 -21.746 -18
2020-09-30 590.086 7.641 -15.858
2020-06-30 545.995 18.538 -12.532
2020-03-31 511.47 32.86 -18.767

AMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRN has a Quality Grade of B, ranking ahead of 80.71% of graded US stocks.
  • AMRN's asset turnover comes in at 0.626 -- ranking 51st of 681 Pharmaceutical Products stocks.
  • CEMI, NEOG, and INSM are the stocks whose asset turnover ratios are most correlated with AMRN.

The table below shows AMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.626 0.793 0.031
2021-03-31 0.628 0.792 0.019
2020-12-31 0.652 0.786 -0.036
2020-09-30 0.641 0.784 -0.042
2020-06-30 0.608 0.781 -0.052
2020-03-31 0.668 0.778 -0.163

AMRN Stock Price Chart Interactive Chart >

Price chart for AMRN

AMRN Price/Volume Stats

Current price $5.16 52-week high $9.25
Prev. close $5.17 52-week low $3.84
Day low $5.11 Volume 1,338,500
Day high $5.24 Avg. volume 4,704,081
50-day MA $5.27 Dividend yield N/A
200-day MA $5.47 Market Cap 2.04B

Amarin Corp. PLC ADR (AMRN) Company Bio


Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.


AMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream


Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Amarin (AMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | October 11, 2021

3 Top Stocks With Upsides Over 50%, According to Wall Street Analysts

When looking for top stocks, instead of traditional valuation measures, look at stocks trading well below their upside potential.

David Cohne on InvestorPlace | October 7, 2021

Amarin Charts Are Charting a Course Toward Improvement

However, traders will need to show a lot of patience if they buy shares of the biopharmaceutical company.

Yahoo | September 24, 2021

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and ReimbursementDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VA

Yahoo | September 22, 2021

Amarin to Participate in September Investment Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C.

Amarin | September 13, 2021

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo 0.19%
3-mo 22.27%
6-mo 4.24%
1-year 0.19%
3-year -74.34%
5-year 72.00%
YTD 5.52%
2020 -77.19%
2019 57.53%
2018 239.40%
2017 30.19%
2016 62.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9147 seconds.